| EBITDA Margin guidance | 23.0% → 24.0% Raised by 1.0 percentage points |
|---|
| Revenue growth | Q2 +39.9% YoY; H1 +45.3%; USD $58Mn, up 5%+ QoQ |
|---|---|
| Margins | Op EBITDA 25.0% vs 24.2% Q1 and 22.9% Q2 FY26 |
| Demand visibility | Management claims strong revenue visibility in coming quarters |
| Management confidence | Upbeat; raised FY27 margin guide; claims strong visibility |
Growth
Revenue +39.9% YoY in Q2 and +45.3% in H1. PAT +67.9% in Q2 and +80.3% in H1. USD revenue $58Mn, up 5%+ QoQ.
Outlook
FY27 Op EBITDA margin guided 24%+ (was 23%+). R&D ₹5,000Mn+ over nine quarters. NWC to normalise to 125-130 days.
Risks
Five USFDA observations at Ambernath; Satara and Pithampur EIRs pending. NWC 117 days; net debt ₹1,159Mn versus net cash at March.
Last quarter's promises, checked
Delivered
- Op EBITDA margin 22%-23% → 25.0% Q2 FY27 (= BEAT)
- Specialty GP share 31%-32% Q2-Q3 FY26, rising → 36% of H1 FY27 GP (= BEAT; periods differ)
Partly delivered
- Pithampur validations by mid-CY26, commercialisation Q1 CY27 → EIR still awaited, ramp unconfirmed (= PARTIAL)
Investor Presentation filed with NSE, NSE: RUBICON. Summary written with AI assistance from the document.
Rubicon Research Ltd: key numbers
- Share price
- ₹1,740.00
- Market cap
- ₹28,803 Cr
- Revenue (annual)
- ₹1,754 Cr
- Net profit (annual)
- ₹246.7 Cr
- P/E (TTM)
- 99.9×Sector 37.9×
- Promoter holding
- 51.25%-8.51% QoQ
- FII holding
- 9.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rubicon Research Ltd
All →Rubicon Research Other Announcement
Rubicon Research filed the India Ratings monitoring agency report for the IPO fresh issue proceeds for the quarter ended September 30, 2026. The agency found no deviation from the stated objects of the issue.
Rubicon Research Q2 FY27 Results: Net Profit ₹90.4 Cr, Up 67.7% YoY
Rubicon Research Ltd reported revenue from operations of ₹576.4 Cr (+39.9% YoY) and net profit of ₹90.4 Cr (+67.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹90.4 Cr · +67.7% YoY
Rubicon Research Employee Stock Options
Rubicon Research Limited granted 68,982 stock options at an exercise price of Rs. 1,374.40 per share. The options vest over five years under the company's 2026 ESOP plan.
Rubicon Research Business Update
Rubicon Research disclosed a USFDA inspection of its Ambernath facility, which issued five procedural Form 483 observations. No monetary penalty or amount is involved.
Rubicon Research Board Meeting Date
Rubicon Research scheduled its Board for November 5, 2026, to consider unaudited financial results for the half year ended September 2026. Trading window closed since October 1.
Rubicon Research Other Announcement
Rubicon Research Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, pursuant to Regulation 31(1)(b) of the LODR Regulations.